文献速递皮肤肿瘤

皮肤中的骚动:黑色素瘤免疫治疗的研发

A Commotion in the Skin: Developing Melanoma Immunotherapies.
PubMed 文献 · J Invest Dermatol · 2022-03-24

黑色素瘤可部分甚至极少完全消退于免疫反应,对通用肿瘤免疫治疗的发展具有关键作用;抗CTLA-4抗体提供了实体瘤可对免疫治疗敏感的证明,抗PD-1抗体带来临床突破,但约半数转移性黑色素瘤患者仍死亡,联合治疗仅部分改善总生存。近期数据显示IFN-γ依赖性细胞周期控制基因诱导缺陷与免疫治疗耐药密切相关。

要点

  • 黑色素瘤是通用肿瘤免疫治疗研发的领先肿瘤。
  • 抗CTLA-4抗体提供了实体瘤可对免疫治疗敏感的证明。
  • 抗PD-1抗体带来肿瘤免疫治疗的临床突破。

核心结论

  • 黑色素瘤对免疫介导的排斥机制研究推动了通用肿瘤免疫治疗的发展。
  • 抗CTLA-4抗体提供了实体瘤可对免疫治疗敏感的证明,抗PD-1抗体带来临床突破。
  • 约半数转移性黑色素瘤患者仍死亡。
  • 联合抗PD-1与抗CTLA-4抗体或靶向治疗仅部分改善总生存。
  • IFN-γ依赖性细胞周期控制基因诱导缺陷与免疫治疗耐药密切相关,可能有助于识别应答患者并开发联合细胞周期抑制剂的新疗法。

研究设计与样本

  • 综述,检索范围原文未报告。

主要发现

  • 黑色素瘤可部分且极少完全消退于免疫反应。
  • 肿瘤特异性新抗原和突变自身抗原(现称肿瘤相关抗原)及其被细胞毒性T淋巴细胞的识别被发现。
  • 黑色素瘤对过继性T细胞治疗和主动肿瘤疫苗(即树突状细胞疫苗)的发展具有关键重要性。
  • 约半数转移性黑色素瘤患者死亡。
  • 联合抗PD-1与抗CTLA-4抗体以增强抗肿瘤免疫应答或联合靶向治疗仅部分改善总生存。

关键数值与推荐

  • 原文未报告具体标准或数值。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Melanomas are malignant tumors that can partly and very rarely completely regress in response to immune responses. Analyzing the mechanisms underlying this immune-mediated rejection, melanomas became leading in developing general cancer immunotherapy. This resulted in the discovery of tumor-specific neoantigens and mutations autoantigens, now called tumor-associated antigens, and their specific recognition by cytotoxic T lymphocytes. Melanomas were of key importance for the development of adoptive T-cell therapy and active tumor vaccines, namely dendritic cell vaccines. Melanoma therapy with antibodies against CTLA-4 provided the proof of concept that solid cancers can be susceptible to cancer immunotherapy, and melanoma therapy with antibodies against PD-1 resulted in the clinical breakthrough of cancer immunotherapy. Still, about half of patients die from metastatic melanoma. Combining anti‒PD-1 with anti‒CTLA-4 antibodies to increase antitumor immune responses or with targeted therapy improves the overall survival only partially. Recent data revealed a close link between defects in the IFN-γ‒dependent induction of cell cycle control genes and resistance to immunotherapy, which may allow for identifying those patients that respond to immunotherapy and to develop novel therapies, combining cancer immunotherapy with cell cycle inhibitors.

来源:J Invest Dermatol,查看原文。版权归原作者所有。

引用

  1. Brenner E, Röcken M. A Commotion in the Skin: Developing Melanoma Immunotherapies. J Invest Dermatol. 2022. PMID: 35339277. doi:10.1016/j.jid.2022.01.025

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。